Concepedia

Author

Jean Helmijr

Erasmus MC Cancer InstituteORCID

Also Known As

Helmijr, Jean C. A., J Helmijr, J. C. A. Helmijr, J.C.A. Helmijr, Jean C. A. Helmijr, Jean C. A. Helmijr (630623), Jean C. Helmijr, Jean C.A. Helmijr, Jean Helmijr

37

Publications

1.2K

Citations

12

H-Index

28

Concepts

All Affiliations

Erasmus MC Cancer InstituteErasmus MCUniversity Medical Center UtrechtKU LeuvenThe Netherlands Cancer Institute
JH

About

Jean Helmijr is an author at Erasmus MC Cancer Institute specializing in medicine, oncology, and tumor biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

648

2

Health Sciences

2

2

188

3

Cell Biology

2

2

437

4

Medical Laboratory Science

1

1

155

5

Obstetrics

1

1

404

Jean Helmijr

×

12

Publications

1.2K

Citations

12

H-Index

YearCitations

Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes

Corine M. Beaufort, Jean Helmijr, Anna Piskorz,

PLoS ONE

2014

404

miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs

Muhammad Riaz, Marijn TM van Jaarsveld, Antoinette Hollestelle,

Breast Cancer Research

2013

225

Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions

Lisanne F. van Dessel, Nick Beije, Jean Helmijr,

Molecular Oncology

2017

155

Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases

Nick Beije, Jean Helmijr, Marjolein J.A. Weerts,

Molecular Oncology

2016

74

Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen

Diana Ramirez-Ardila, Jean Helmijr, Maxime P. Look,

Breast Cancer Research and Treatment

2013

56

High‐throughput isolation of circulating tumor <scp>DNA</scp>: a comparison of automated platforms

Lisanne F. van Dessel, Silvia Rita Vitale, Jean Helmijr,

Molecular Oncology

2018

52

Optimizing Nanopore sequencing-based detection of structural variants enables individualized circulating tumor DNA-based disease monitoring in cancer patients

Jose Espejo Valle-Inclán, Christina Stangl, Anouk C. de Jong,

Genome Medicine

2021

45

TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer

Silvia Rita Vitale, Floris H. Groenendijk, Ronald van Marion,

Biomolecules

2020

37

Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen

Maurice P.H.M. Jansen, John W.M. Martens, Jean Helmijr,

Oncotarget

2016

33

LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome

Diana Ramirez-Ardila, Kirsten Ruigrok-Ritstier, Jean Helmijr,

Molecular Oncology

2016

33

Page 1